ArticleCureus2026
Intensive Care Management of Anti-Mi2-Positive Dermatomyositis: Lupus Overlap Syndrome.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report the case of a 49-year-old woman diagnosed with an autoimmune overlap syndrome characterized by anti-Mi2-positive dermatomyositis and systemic lupus erythematosus (SLE), presenting with extreme hyper-creatine kinase (CK) levels (>3000 U/L), progressive muscle weakness, and respiratory failure requiring intensive care management. Muscle biopsy revealed chronic inflammatory myopathy with perifascicular necrosis, and immunologic testing showed antinuclear antibody (ANA) 1:640, anti-double-stranded (ds)DNA, and anti-Mi2 positivity, confirming the diagnosis. During her clinical course, she developed hypoxemic respiratory failure, multiple endocrine dysfunctions (central hypopituitarism and autoimmune hypothyroidism), and nosocomial infections, all of which were successfully controlled. She received intravenous immunoglobulin (IVIG) therapy followed by five sessions of therapeutic plasma exchange (PLEX) (1.5 plasma volumes replaced with albumin), achieving partial muscle strength recovery, a 60% reduction in CK levels, and hemodynamic stabilization. This case represents a rare and severe form of dermatomyositis-lupus overlap syndrome with critical evolution and favorable response to combined immunomodulatory therapy. It highlights the importance of early diagnosis, multidisciplinary management, and the timely use of therapeutic PLEX as a rescue treatment for refractory autoimmune diseases in critically ill patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.